Sentinel lymph node mapping in endometrial cancer: comparison of fluorescence dye with traditional radiocolloid and blue.
Andrea PapadiaMaria Luisa GasparriAlessandro BudaMichael D MuellerPublished in: Journal of cancer research and clinical oncology (2017)
Sentinel lymph node (SLN) mapping in endometrial cancer (EMCA) is rapidly gaining acceptance in the clinical community. As compared to a full lymphadenectomy in every patient, to a selective lymphadenectomy after frozen section of uterus in selected patients with intrauterine risk factors or to a strategy in which a lymphadenectomy is always omitted, SLN mapping seems to be a reasonable and oncologically safe middle ground. Various protocols can be used when applying an SLN mapping. In this manuscript we review the characteristics, toxicity and clinical impact of technetium-99m radiocolloid (Tc-99m), of the blue dyes (methylene blue, isosulfan blue and patent blue) and of indocyanine green (ICG). ICG has an excellent toxicity profile, has higher overall and bilateral detection rates as compared to blue dyes and higher bilateral detection rates as compared to a combination of Tc-99m and blue dye. The detrimental effect of BMI on the detection rates is attenuated when ICG is used as a tracer. The ease of use of the ICG SLN mapping is perceived by the patients as a better quality of care delivered. Whenever possible, ICG should be favored over the other tracers for SLN mapping in EMCA patients.
Keyphrases
- sentinel lymph node
- endometrial cancer
- lymph node
- early stage
- neoadjuvant chemotherapy
- high resolution
- fluorescence imaging
- high density
- end stage renal disease
- risk factors
- healthcare
- newly diagnosed
- ejection fraction
- oxidative stress
- prognostic factors
- mental health
- radiation therapy
- physical activity
- real time pcr
- photodynamic therapy
- body mass index
- label free
- locally advanced
- loop mediated isothermal amplification
- pain management
- sensitive detection
- robot assisted
- energy transfer